SEARCH RESULT

Total Matching Records found : 695

SC’s Novartis judgement renews focus on accessible medicine

The recent Supreme Court judgment dismissing pharma giant Novartis’ claim for patent protections in India for its award-winning and prohibitively priced anti-leukemia drug Glivec has renewed the focus on accessibly-priced drugs – in particular the failure of the Indian Public Healthcare system and health policy to ensure affordable drugs for all. Studies show that as much as 70% of health spending in India comes from out-of-pocket payments, with 50-80% of...

More »

More battles in store-Aarti Dhar

-The Hindu Well before the Supreme Court rejected Novartis' application for patent for Glivec (Gleevec in the U.S.), drawing attention to the dichotomy of generic and patented drugs, activists have been demanding access to expensive drugs used in the treatment of cancer, hepatitis C and serious HIV. Trastuzumab is one such, used in the treatment of HER2+ type of breast cancer, which affects about one in four patients with the disease. Rough...

More »

What Right To Education? Failing to meet the prescribed norms, half of the existing schools will lose their recognition -Arvind Panagariya

-The Times of India     The three-year compliance period for the Right to Education (RTE) Act is just over. What has the Act accomplished? Sadly, not very much that is positive. A key provision in the law abolishes board examinations and grants automatic promotion to each child to the next grade at the end of the academic year. It also requires the award of a diploma to all at the end of eight...

More »

Glivec lesson for pharma: Patented drugs must be priced smartly-Kiran Mazumdar Shaw

-The Economic Times To ensure access to healthcare for all, India must harness innovation in discovering drugs, in developing therapeutics and in delivering affordable healthcare. It is in the light of these facts that one should evaluate the impact of the Indian Supreme Court's ruling in the case involving patent protection for Novartis AG's cancer drug, Glivec. Glivec was the first-of-its-kind cancer drug for leukaemia patients with patent protection in nearly 40...

More »

CAG rips into Delhi govt for messing up services, utilities

-The Times of India The report of the comptroller and auditor general (CAG) on the Delhi government for the year ended March 2012 is a scathing indictment of many departments and public utilities. Healthcare, transport, power, water and sewage and even showcase infrastructure projects and schemes have been put under the lens and the picture that has emerged is not all that pretty. The report was tabled in the Delhi assembly...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close